Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19
Primary Purpose
COVID-19
Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Hydroxychloroquine plus Nitazoxanide
Standard care
Sponsored by
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring Hydroxychloroquine, Nitazoxanide, COVID-19
Eligibility Criteria
Inclusion Criteria:
- Confirmed cases of COVID-19 (Positive RT-PCR)
- Newly diagnosed symptomatic patients.
- Adults (18-65 Years old)
- Both sexes
Exclusion Criteria:
- Patients with abnormal liver function (ALT, AST), chronic kidney disease or dialysis (CrCl< 30 ml/min)
- Pregnant women or women who are breastfeeding
- Immunocompromised patients taking medication upon screening
- Subjects with comorbid condition like hypertension, cardiovascular disease, diabetes mellites, asthma, COPD, malignancy
- Patients having allergy to Hydroxychloroquine and/or Nitazoxanide
- Patients with contraindication towards the study medication including retinopathy, G6PD deficiency and QT prolongation.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Hydroxychloroquine plus Nitazoxanide
Standard care
Arm Description
200 mg of Hydroxychloroquine orally three times daily for 10 days plus 500 mg of Nitazoxanide orally twice daily for 6 days
Standard care delivered in the COVID-19 isolation hospitals.
Outcomes
Primary Outcome Measures
Number of patients with COVID-19-negative PCR
PCR analysis of COVID-19 RNA in patients
Secondary Outcome Measures
Number of patients with improved respiratory rate
improved breaths per minute for the patients
Number of patients with improved PaO2
Change in PaO2 in mmHg of the patients
Number of patients with normalized Serum IL6
Serum IL6 in pg/mL of the patients
Number of patients with normalized Serum TNFα
Serum TNFα in pg/mL of the patients
Number of patients with normalized Serum iron
Serum iron in microgram/dL of the patients
Number of patients with normalized Serum ferritin
Serum ferritinin microgram/L of the patients
Number of patients with normalized International normalized ratio "INR" for prothrombin time
International normalized ratio "INR" for prothrombin time of 2
Number of patients with normalized complete blood count "CBC"
CBC for lymphocyte count in cells/microliter
The Mortality rate among treated patients
Mortality rate [number of dead patients/total number of treated patients]
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04361318
Brief Title
Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19
Official Title
Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope
Study Type
Interventional
2. Study Status
Record Verification Date
April 2020
Overall Recruitment Status
Unknown status
Study Start Date
May 2020 (Anticipated)
Primary Completion Date
October 2020 (Anticipated)
Study Completion Date
December 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tanta University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In December 2019, a new infectious respiratory disease emerged in Wuhan, Hubei province, China. An initial cluster of infections was linked to Huanan seafood market, potentially due to animal contact. Subsequently, human-to-human transmission occurred and the disease, now termed coronavirus disease 19 (COVID-19) rapidly spread within China and all over the world. A novel coronavirus, SARS-coronavirus 2 (SARS-CoV-2), which is closely related to SARS-CoV, was detected in patients and is believed to be the etiologic agent of the new lung disease. The causative agent of the current COVID-19 pandemic, SARS-CoV-2, is a single stranded positive sense RNA virus that is closely related to severe acute respiratory syndrome coronavirus (SARS-CoV).
Detailed Description
Selected Drugs
Hydroxychloroquine (an analog of chloroquine) has been demonstrated to have an anti-SARS-CoV activity in vitro. Hydroxychloroquine clinical safety profile is better than that of chloroquine (during long-term use) and allows higher daily dose and has fewer concerns about drug-drug interactions. Hydroxychloroquine has long-term safety (600 mg/day for 12 to 18 months was safe). Hydroxychloroquine effectively inhibited both the entry, transport and the post-entry stages of SARS-CoV-2, similar to the chloroquine, and one study found Hydroxychloroquine to be a more potent agent than chloroquine in inhibiting SARS-CoV-2 in vitro. Hydroxychloroquine acts as a weak base that can change the pH of acidic intracellular organelles including endosomes/lysosomes, essential for the membrane fusion. Besides, the significant decrease in the production of pro-inflammatory markers and cytokines with Hydroxychloroquine has made this agent a successful disease modifying anti-inflammatory agent in the treatment of various autoimmune diseases. An additional issue to be considered in severely sick patients is cytokine storm associated with disease severity of SARS-CoV-2.
There are no currently available data from randomized clinical trials (RCTs) to inform clinical guidance on the use, dosing, or duration of Hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection. Although optimal dosing and duration of Hydroxychloroquine for treatment of COVID-19 are unknown, some U.S. clinicians have reported anecdotally different Hydroxychloroquine dosing such as 400 mg twice daily on day one, then daily for 5 days; 400 mg twice daily on day one, then 200 mg twice daily for 4 days; 600 mg twice daily on day one, then 400 mg daily on days 2-5. In a recent clinical trial, Hydroxychloroquine sulfate 200 mg, three times per day during ten days was used in patients with COVID-19.
Nitazoxanide is originally developed as an antiprotozoal agent and has a broad-spectrum antiviral activity undergoing development for the treatment of influenza and other viral respiratory infections. In addition to its antiviral activity, Nitazoxanide inhibits the production of pro-inflammatory cytokines TNF-α, IL-2, IL-4, IL-5, IL-6, IL-8 and IL-10 in peripheral blood mononuclear cells. Nitazoxanide could improve outcomes in patients infected with MERS-CoV by suppressing overproduction of pro-inflammatory cytokines, including IL-6. Nitazoxanide has been tested in clinical setting for the treatment of acute uncomplicated influenza, where the subjects received either 600 or 300 mg of Nitazoxanide or placebo orally twice daily for five days and were followed for 28 days. Subjects who received Nitazoxanide 600 mg twice daily experienced shorter times to alleviation of symptoms compared with subjects who received 300 mg Nitazoxanide twice daily, which in turn, was shorter than placebo.
According to the National Health Commission of the People's Republic of China, there is lack of effective antiviral therapy against COVID-19. Nearly all patients who suffered from COVID-19-associated pneumonia accepted oxygen therapy and WHO recommended extracorporeal membrane oxygenation (ECMO) to patients with refractory hypoxemia. Rescue treatment with convalescent plasma and immunoglobulin G are delivered to some critical cases according to their condition.
The rationale of the use of Hydoxychloroquine and Nitazoxanide combination for treatment of COVID-19 infected patients is based on the antiviral and anti-inflammatory activity of the selected drugs. Since the two drugs exhibit different modes of action, it would be of value in containing the viral infection through targeting different sites in the pathophysiology of the disease.
Diagnostic criteria
The viral research institution in China has conducted preliminary identification of the SARS-CoV-2 through the classical Koch's postulates and observing its morphology through electron microscopy. So far, the golden clinical diagnosis method of COVID-19 is nucleic acid detection in the nasal and throat swab sampling or other respiratory tract samplings by real-time PCR and further confirmation by next-generation sequencing.
Side effects of Hydroxychloroquine
The most common adverse effects are mild nausea and occasional stomach cramps with mild diarrhea, reduced appetite and vomiting
The most serious adverse effects are retinopathy and heart problems
Long term use may cause liver toxicity Contraindications of Hydroxychloroquine
Heart conditions, diabetes or psoriasis.
The drug transfers into breast milk so should be used with care by pregnant or nursing women
Interactions of Hydroxychloroquine
Antacids may decrease the absorption of Hydroxychloroquine.
Both neostigmine and pyridostigmine antagonize the action of Hydroxychloroquine.
There may be a link between Hydroxychloroquine and hemolytic anemia in those with glucose-6-phosphate dehydrogenase deficiency.
Digoxin; concomitant administration with Hydroxychloroquine may result in increased serum digoxin levels.
Insulin or antidiabetic drugs; concomitant administration with Hydroxychloroquine may enhance the effects of the hypoglycemic treatment.
Hydroxychloroquine prolongs the QT interval and may increase the risk of inducing ventricular arrhythmias if used concurrently with other arrhythmogenic drugs.
Mefloquine and other drugs that lower the convulsive threshold, when co-administered with Hydroxychloroquine, there may be an increased risk of convulsions.
Concurrent use of Hydroxychloroquine with antiepileptics may impair the antiepileptic activity.
Cyclosporin when used concomitantly with Hydroxychloroquine, an increased plasma cyclosporin level was reported.
Side effects of Nitazoxanide
The most common adverse effects are GIT as nausea and occasional stomach cramps with mild diarrhea, reduced appetite and vomiting. Nervous system side effects as headache, dizziness, somnolence, insomnia, tremor, and hypesthesia have been reported in less than 1% of the patients.
Contraindications of Nitazoxanide
There are no data on the excretion of Nitazoxanide into human milk. The manufacturer recommends that caution be used when administering Nitazoxanide to nursing women.
Tizoxanide (the active metabolite of Nitazoxanide) is highly bound to plasma protein (> 99.9%). Therefore, it is necessary to monitor for adverse reactions when administering Nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).
Warning
Nitazoxanide should be used with caution in patients with significant renal and hepatic impairment.
Research Objectives
The pandemic disease COVID-19 is particularly of major importance in Egypt where a heavy population lives. There is an acute need for comprehensive, continuous, and cost-effective health care delivery for infected people. Early detection and strategies for prevention of progression of COVID-19 would make a major difference for these patients and would also be economically beneficial for a resource-constrained country.
This research proposal was employed as a practical strategy for providing a suitable drug combination for possible treatment of COVID-19 infected patients. This drug combination may help to prevent the progression of respiratory complications. This can be achieved through different goals as follows:
Screening of different drugs related to different pharmacological classes depending on its possible activity against COVID-19 virus.
Providing cost-effective and easy-to-implement treatment strategy for infected patients and/or patients with high risk of developing respiratory failure.
Finally, this clinical strategy remains an important goal in improving the Egyptian health state which can save people life and save a lot of money.
Scope of Work
The scope of work will be conducted through:
Use of new drug combination of Hydroxychloroquine and Nitazoxanide for treatment of COVID-19 infected people. Since the two drugs exhibit different modes of action, it would be of value in containing the viral infection through targeting different sites in the pathophysiology of the disease.
Evaluation of the effect of new drug combination on the symptomatic treatment of newly diagnosed COVID-19 patients through a clinical trial designed according to WHO (clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected) interim guidance published at 13 March 2020.
Investigating the impact of new drug combination on the prevention of severe compilations such as acute respiratory distress syndrome (ARDS).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19
Keywords
Hydroxychloroquine, Nitazoxanide, COVID-19
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Masking Description
a double blind randomized controlled parallel study
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Hydroxychloroquine plus Nitazoxanide
Arm Type
Experimental
Arm Description
200 mg of Hydroxychloroquine orally three times daily for 10 days plus 500 mg of Nitazoxanide orally twice daily for 6 days
Arm Title
Standard care
Arm Type
Active Comparator
Arm Description
Standard care delivered in the COVID-19 isolation hospitals.
Intervention Type
Combination Product
Intervention Name(s)
Hydroxychloroquine plus Nitazoxanide
Other Intervention Name(s)
drug therapy
Intervention Description
Both hydroxychloroquine & nitazoxanide will be administered orally to participating patients
Intervention Type
Other
Intervention Name(s)
Standard care
Intervention Description
Oxygen administered via ventilator. In addition, antipyretic "paracetamol" may be added if necessary
Primary Outcome Measure Information:
Title
Number of patients with COVID-19-negative PCR
Description
PCR analysis of COVID-19 RNA in patients
Time Frame
within 10 days to become PCR negative
Secondary Outcome Measure Information:
Title
Number of patients with improved respiratory rate
Description
improved breaths per minute for the patients
Time Frame
within 30 days
Title
Number of patients with improved PaO2
Description
Change in PaO2 in mmHg of the patients
Time Frame
within 30 days
Title
Number of patients with normalized Serum IL6
Description
Serum IL6 in pg/mL of the patients
Time Frame
within 30 days
Title
Number of patients with normalized Serum TNFα
Description
Serum TNFα in pg/mL of the patients
Time Frame
within 30 days
Title
Number of patients with normalized Serum iron
Description
Serum iron in microgram/dL of the patients
Time Frame
within 30 days
Title
Number of patients with normalized Serum ferritin
Description
Serum ferritinin microgram/L of the patients
Time Frame
within 30 days
Title
Number of patients with normalized International normalized ratio "INR" for prothrombin time
Description
International normalized ratio "INR" for prothrombin time of 2
Time Frame
within 30 days
Title
Number of patients with normalized complete blood count "CBC"
Description
CBC for lymphocyte count in cells/microliter
Time Frame
within 30 days
Title
The Mortality rate among treated patients
Description
Mortality rate [number of dead patients/total number of treated patients]
Time Frame
within 30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Confirmed cases of COVID-19 (Positive RT-PCR)
Newly diagnosed symptomatic patients.
Adults (18-65 Years old)
Both sexes
Exclusion Criteria:
Patients with abnormal liver function (ALT, AST), chronic kidney disease or dialysis (CrCl< 30 ml/min)
Pregnant women or women who are breastfeeding
Immunocompromised patients taking medication upon screening
Subjects with comorbid condition like hypertension, cardiovascular disease, diabetes mellites, asthma, COPD, malignancy
Patients having allergy to Hydroxychloroquine and/or Nitazoxanide
Patients with contraindication towards the study medication including retinopathy, G6PD deficiency and QT prolongation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kamal Okasha, MD, PhD
Phone
+201004706770
Email
vp_research@unv.tanta.edu.eg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kamal Okasha, MD, PhD
Organizational Affiliation
Tanta University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
31986264
Citation
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;:
Results Reference
background
PubMed Identifier
31986257
Citation
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24. No abstract available. Erratum In: Lancet. 2020 Jan 29;:
Results Reference
background
PubMed Identifier
32067043
Citation
Yu P, Zhu J, Zhang Z, Han Y. A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period. J Infect Dis. 2020 May 11;221(11):1757-1761. doi: 10.1093/infdis/jiaa077.
Results Reference
background
PubMed Identifier
32251768
Citation
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
Results Reference
background
PubMed Identifier
16640347
Citation
Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006 May 4;49(9):2845-9. doi: 10.1021/jm0601856.
Results Reference
background
PubMed Identifier
26992838
Citation
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016 Jun;123(6):1386-94. doi: 10.1016/j.ophtha.2016.01.058. Epub 2016 Mar 16.
Results Reference
background
PubMed Identifier
32150618
Citation
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
Results Reference
background
PubMed Identifier
9927100
Citation
Raoult D, Houpikian P, Tissot Dupont H, Riss JM, Arditi-Djiane J, Brouqui P. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med. 1999 Jan 25;159(2):167-73. doi: 10.1001/archinte.159.2.167.
Results Reference
background
PubMed Identifier
32194981
Citation
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020. No abstract available.
Results Reference
background
PubMed Identifier
32145363
Citation
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4. No abstract available.
Results Reference
background
PubMed Identifier
32205204
Citation
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
Results Reference
background
PubMed Identifier
25108173
Citation
Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014 Oct;110:94-103. doi: 10.1016/j.antiviral.2014.07.014. Epub 2014 Aug 7.
Results Reference
background
PubMed Identifier
22430099
Citation
Hong SK, Kim HJ, Song CS, Choi IS, Lee JB, Park SY. Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice. Int Immunopharmacol. 2012 May;13(1):23-7. doi: 10.1016/j.intimp.2012.03.002. Epub 2012 Mar 17.
Results Reference
background
PubMed Identifier
32113510
Citation
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27. No abstract available.
Results Reference
background
PubMed Identifier
31950516
Citation
Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020 Apr;92(4):401-402. doi: 10.1002/jmv.25678. Epub 2020 Feb 12. No abstract available.
Results Reference
background
Learn more about this trial
Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19
We'll reach out to this number within 24 hrs